ReviewClinical rheumatology2015
Idiopathic inflammatory myopathies-a review.
Review in Clinical rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- The Function of Poly (U) Binding Splicing Factor 60 (PUF60) in Disease Regulation.Anti-cancer agents in medicinal chemistry · 2026Review
- Concentric macro EMG role in electrodiagnostic evaluation of inflammatory myopathies.European journal of translational myology · 2025Article
- Idiopathic Inflammatory Myopathy-Molecular Mechanisms Underlying Its Pathogenesis and Physical Therapy Effects.International journal of molecular sciences · 2025Review
- Nephrotic Syndrome as an Extramuscular Manifestation of Anti-EJ Antibody-Positive Dermatomyositis: A Case Report and Review of the Literature.Case reports in rheumatology · 2022Article
- Altered peripheral helper T cells in peripheral blood and muscle tissue of the patients with dermatomyositis.Clinical and experimental medicine · 2021Article
- Article
- Muscle assessment using multi-frequency bioimpedance in a healthy Danish population aged 20-69 years: a powerful non-invasive tool in sports and in the clinic.Physiological reports · 2019Article
- The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy.Clinical rheumatology · 2018Article
- Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis.Chinese medical journal · 2017Article
- Toll-Like Receptor 4-Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Inflammatory Development of Polymyositis by Mediating Interferon-γ and Interleukin-17A in Humans and Experimental Autoimmune Myositis Mouse Model.Frontiers in neurology · 2017Article
- Laboratory Studies in Autoimmune Diseases.Missouri medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The idiopathic inflammatory myopathies (IIM) constitute a subset of autoimmune conditions primarily affecting muscle, along with many extra-muscular manifestations. Proximal muscle weakness is the dominant symptom in the IIM. In addition, many patients will have cutaneous manifestations, pulmonary manifestations, and arthritis. There is an increased incidence of malignancy with the IIM. Diagnostic tools beyond history and physical exam include serum muscle enzyme and autoantibody testing, magnetic resonance imaging (MRI) of the extremities, ultrasound, neurologic testing, and muscle biopsy. Several options for treatment are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.